Dynavax Technologies Co. (NASDAQ:DVAX) Stock Position Lifted by Rhumbline Advisers

Rhumbline Advisers grew its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 4.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 305,718 shares of the biopharmaceutical company’s stock after buying an additional 13,597 shares during the period. Rhumbline Advisers owned about 0.23% of Dynavax Technologies worth $3,904,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. US Bancorp DE raised its position in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,034 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies during the 3rd quarter worth approximately $45,000. GAMMA Investing LLC increased its position in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 1,457 shares during the period. Nisa Investment Advisors LLC increased its position in Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 1,679 shares during the period. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Dynavax Technologies in the 4th quarter valued at approximately $71,000. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

NASDAQ DVAX opened at $13.79 on Friday. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.05. The stock’s 50-day moving average is $12.87 and its two-hundred day moving average is $12.09. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market cap of $1.71 billion, a P/E ratio of 76.61 and a beta of 1.32.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The business had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. On average, analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the company. The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their target price for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a research note on Friday, February 21st.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.